- Home
- ZEPP vs APLT Comparison
ZEPP vs APLT Comparison
Compare ZEPP & APLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZEPP
- APLT
- Stock Information
- Founded
- ZEPP 2013
- APLT 2016
- Country
- ZEPP Netherlands
- APLT United States
- Employees
- ZEPP N/A
- APLT N/A
- Industry
- ZEPP Computer Manufacturing
- APLT Biotechnology: Pharmaceutical Preparations
- Sector
- ZEPP Technology
- APLT Health Care
- Exchange
- ZEPP Nasdaq
- APLT Nasdaq
- Market Cap
- ZEPP 34.1M
- APLT 37.5M
- IPO Year
- ZEPP N/A
- APLT 2019
- Fundamental
- Price
- ZEPP $2.43
- APLT $0.35
- Analyst Decision
- ZEPP
- APLT Buy
- Analyst Count
- ZEPP 0
- APLT 7
- Target Price
- ZEPP N/A
- APLT $6.10
- AVG Volume (30 Days)
- ZEPP 19.8K
- APLT 1.4M
- Earning Date
- ZEPP 05-19-2025
- APLT 08-06-2025
- Dividend Yield
- ZEPP N/A
- APLT N/A
- EPS Growth
- ZEPP N/A
- APLT N/A
- EPS
- ZEPP N/A
- APLT N/A
- Revenue
- ZEPP $181,183,000.00
- APLT $265,000.00
- Revenue This Year
- ZEPP $758.69
- APLT $1,768.13
- Revenue Next Year
- ZEPP N/A
- APLT $292.85
- P/E Ratio
- ZEPP N/A
- APLT N/A
- Revenue Growth
- ZEPP N/A
- APLT N/A
- 52 Week Low
- ZEPP $2.06
- APLT $0.30
- 52 Week High
- ZEPP $4.38
- APLT $10.62
- Technical
- Relative Strength Index (RSI)
- ZEPP 47.59
- APLT 42.17
- Support Level
- ZEPP $2.25
- APLT $0.34
- Resistance Level
- ZEPP $2.44
- APLT $0.38
- Average True Range (ATR)
- ZEPP 0.14
- APLT 0.02
- MACD
- ZEPP 0.00
- APLT -0.00
- Stochastic Oscillator
- ZEPP 49.90
- APLT 7.14
About ZEPP Zepp Health Corporation
Zepp Health Corp is engaged in the business of manufacturing smart health wearable products. The company operates in one segment which is Amazfit-branded products. The product portfolio includes smartwatches and fitness bands.
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.